L-arginine supplementation and metabolism in asthma

Nicholas Kenyon, Michael Last, Jennifer M. Bratt, Vivian W. Kwan, Erin O'Roark, Angela Linderholm

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebocontrolled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10-3 vs. 1.1 ± 0.2 × 10-3 μmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 μmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10-1 vs. 2.6 ± 0.6 × 10-1 μmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.

Original languageEnglish (US)
Pages (from-to)187-201
Number of pages15
JournalPharmaceuticals
Volume4
Issue number1
DOIs
StatePublished - 2011

Fingerprint

Arginine
Asthma
Nitric Oxide
Serum
Peak Expiratory Flow Rate
Ornithine
Spirometry
Nitric Oxide Synthase
Chronic Disease
Placebos
Inflammation
Amino Acids
Lung

Keywords

  • ADMA
  • Arginase
  • Asthma
  • L-arginine
  • Nitric oxide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Kenyon, N., Last, M., Bratt, J. M., Kwan, V. W., O'Roark, E., & Linderholm, A. (2011). L-arginine supplementation and metabolism in asthma. Pharmaceuticals, 4(1), 187-201. https://doi.org/10.3390/ph4010187

L-arginine supplementation and metabolism in asthma. / Kenyon, Nicholas; Last, Michael; Bratt, Jennifer M.; Kwan, Vivian W.; O'Roark, Erin; Linderholm, Angela.

In: Pharmaceuticals, Vol. 4, No. 1, 2011, p. 187-201.

Research output: Contribution to journalArticle

Kenyon, N, Last, M, Bratt, JM, Kwan, VW, O'Roark, E & Linderholm, A 2011, 'L-arginine supplementation and metabolism in asthma', Pharmaceuticals, vol. 4, no. 1, pp. 187-201. https://doi.org/10.3390/ph4010187
Kenyon N, Last M, Bratt JM, Kwan VW, O'Roark E, Linderholm A. L-arginine supplementation and metabolism in asthma. Pharmaceuticals. 2011;4(1):187-201. https://doi.org/10.3390/ph4010187
Kenyon, Nicholas ; Last, Michael ; Bratt, Jennifer M. ; Kwan, Vivian W. ; O'Roark, Erin ; Linderholm, Angela. / L-arginine supplementation and metabolism in asthma. In: Pharmaceuticals. 2011 ; Vol. 4, No. 1. pp. 187-201.
@article{f3627bf29b6f4c9e88281390418207c3,
title = "L-arginine supplementation and metabolism in asthma",
abstract = "L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebocontrolled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10-3 vs. 1.1 ± 0.2 × 10-3 μmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 μmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10-1 vs. 2.6 ± 0.6 × 10-1 μmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.",
keywords = "ADMA, Arginase, Asthma, L-arginine, Nitric oxide",
author = "Nicholas Kenyon and Michael Last and Bratt, {Jennifer M.} and Kwan, {Vivian W.} and Erin O'Roark and Angela Linderholm",
year = "2011",
doi = "10.3390/ph4010187",
language = "English (US)",
volume = "4",
pages = "187--201",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - L-arginine supplementation and metabolism in asthma

AU - Kenyon, Nicholas

AU - Last, Michael

AU - Bratt, Jennifer M.

AU - Kwan, Vivian W.

AU - O'Roark, Erin

AU - Linderholm, Angela

PY - 2011

Y1 - 2011

N2 - L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebocontrolled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10-3 vs. 1.1 ± 0.2 × 10-3 μmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 μmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10-1 vs. 2.6 ± 0.6 × 10-1 μmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.

AB - L-Arginine, the amino acid substrate for nitric oxide synthase, has been tested as a therapeutic intervention in a variety of chronic diseases and is commonly used as a nutritional supplement. In this study, we hypothesized that a subset of moderate to severe persistent asthma patients would benefit from supplementation with L-arginine by transiently increasing nitric oxide levels, resulting in bronchodilation and a reduction in inflammation. The pilot study consisted of a 3 month randomized, double-blind, placebocontrolled trial of L-arginine (0.05 g/kg twice daily) in patients with moderate to severe asthma. We measured spirometry, exhaled breath nitric oxide, serum arginine metabolites, questionnaire scores, daily medication use and PEFR with the primary endpoint being the number of minor exacerbations at three months. Interim analysis of the 20 subjects showed no difference in the number of exacerbations, exhaled nitric oxide levels or lung function between groups, though participants in the L-arginine group had higher serum L-arginine at day 60 (2.0 ± 0.6 × 10-3 vs. 1.1 ± 0.2 × 10-3 μmol/L, p < 0.05), ornithine at day 30 (2.4 ± 0.9 vs. 1.2 ± 0.3 μmol/L serum, p < 0.05) and ADMA at day 30 (6.0 ± 1.5 × 10-1 vs. 2.6 ± 0.6 × 10-1 μmol/L serum, p < 0.05) on average compared to the placebo group. The study was terminated prematurely. Supplementing asthma subjects with L-arginine increases plasma levels; whether subgroups might benefit from such supplementation requires further study.

KW - ADMA

KW - Arginase

KW - Asthma

KW - L-arginine

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=79551589237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551589237&partnerID=8YFLogxK

U2 - 10.3390/ph4010187

DO - 10.3390/ph4010187

M3 - Article

AN - SCOPUS:79551589237

VL - 4

SP - 187

EP - 201

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 1

ER -